The significance of alpha‐fetoprotein and other tumour markers in differential immunocytochemistry of primary liver tumours

Brumm, C.; Schulze, Cornelia; Karina, Charels; Morohoshi, Toshio; Klöppel, Günter

doi:10.1111/j.1365-2559.1989.tb02186.x

Cited by 88 publications

(56 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vimentin and bile duct-type cytokeratin expressions were scattered in HCC components. These findings in primary hepatic tumors may be interpreted in the context of their immaturity [2]. Such phenotypic variations of tumor cells in the present case may represent the stem cell nature of the neoplastic cells.…”

supporting

confidence: 54%

Combined Hepatocellular and Cholangiocellular Carcinoma in a Dog.

2001

View full text Add to dashboard Cite

ABSTRACT. A transitional type of combined hepatocellular and cholangiocellular carcinoma developed in a 12-year-old male Yorkshire terrier dog. The tumor was histologically composed of both hepatocellular carcinoma and cholangiocellular carcinoma components, and both elements were closely intermingled. Intraluminal mucin accumulation in cytokeratin-positive tubular/glandular structures was observed within the cholangiocellular carcinoma components and this feature was useful histological marker for a differential diagnosis between combined hepatocellular and cholangiocellular carcinoma and a pseudoglandular type of hepatocellular carcinoma. This primary hepatic tumor is extremely rare in dogs.

show abstract

supporting

confidence: 54%

Combined Hepatocellular and Cholangiocellular Carcinoma in a Dog.

2001

View full text Add to dashboard Cite

show abstract

“…Positive immunostaining for AFP has been reported to be present in 2 to 61% of HCC (18). Expression of AFP can be focal and weak, leading to poor sensitivity, especially in small biopsies (2,7). Expression of AFP may be related to tumor grade, with higher grade HCC expressing AFP more frequently than lower grade tumors.…”

Section: Discussionmentioning

confidence: 99%

“…Immunohistochemical panels have been used to separate these tumors with variable success. ␣-Fetoprotein (AFP); polyclonal carcinoembryonic antigen (pCEA); and cytokeratins (CK) 7,8,18,19, and 20 are among some of the more commonly used markers in these panels (1)(2)(3)(4)(5)(6)(7)(8).…”

mentioning

confidence: 99%

Immunohistochemical Analysis of Hepatocellular and Adenocarcinoma in the Liver: MOC31 Compares Favorably with Other Putative Markers

Young

Proca

et al. 2000

Modern Pathology

View full text Add to dashboard Cite

Distinguishing hepatocellular carcinoma (HCC) from metastatic adenocarcinoma (MA) and cholangiocarcinoma (CC) can, at times, be difficult and sometimes requires immunohistochemical analysis. Recently, MOC31, an antibody directed against a cell surface glycoprotein, has been shown to be useful in separating HCC from both MA and CC; however, no study has compared MOC31 and other frequently used immunostains. We compare MOC31 with other commonly used immunostains for HCC, MA, and CC. Formalin-fixed, paraffin-embedded tissue sections from 57 previously characterized hepatic neoplasms (13 HCC, 14 CC, 3 combined HCC-CC, and 27 MA) were immunostained with antibodies directed against MOC31, cytokeratin (CK) 7, CK20, ␣-fetoprotein (AFP), polyclonal carcinoembryonic antigen, Ber-EP4, and Factor XIII-A. Two pathologists reviewed slides, and positivity was defined as more than 1% of cells staining with the appropriate pattern. Positive MOC31 immunostaining was seen in 0 of 13 HCC, 13 of 14 CC, 3 of 3 HCC-CC, and 27 of 27 MA; the staining was strong and diffuse. CK20 reactivity was observed in 0 of 13 HCC, 2 of 14 CC, 0 of 3 HCC-CC, and 12 of 27 MA; CK7 immunostained 4 of 13 HCC, 13 of 14 CC, 3 of 3 HCC-CC, and 15 of 27 MA; AFP was detected in 4 of 13 HCC and 2 of 3 HCC-CC, whereas all CC and MA were negative; polyclonal carcinoembryonic antigen showed immunoreactivity in 12 of 13 HCC and 3 of 3 HCC-CC in a canalicular pattern, whereas diffuse positivity was identified in 13 of 14 CC and 26 of 27 MA; Ber-EP4 immunostained 1 of 13 HCC, 14 of 14 CC, 2 of 3 HCC-CC, and 26 of 27 MA; and Factor XIII-A was negative in all HCC, CC, and MA. MOC31 expression distinguished HCC from adenocarcinoma in 56 of 57 cases. AFP was specific for HCC but was not sensitive. CK7 and CK20 have limited utility in distinguishing HCC from CC or MA, and Factor XIII-A is not useful. Ber-EP4 staining was similar to MOC31, but one HCC did stain with Ber-EP4. Polyclonal CEA yields similar numerical results as MOC31, but the focal nature of the staining and occasional difficulty in evaluating the pattern can make interpretation problematic. We conclude that MOC31 should be a component of the immunohistochemical panel to distinguish HCC from CC and MA.

show abstract

“…To seek the possibility to use GPC3 immunostaining to detect HCC component (cp) in CHC, combination of antibodies against GPC3, AFP, HepPar1, CK7 and CK17 were used. In addition to AFP, HepPar1 is frequently used as marker for HCC (4)(5)(6)(7)(8) and CK 7 and CK19 for ICC (9)(10)(11).…”

Section: Gpc3 Expression Was Observed Specifically In Pathological Hcmentioning

confidence: 99%

“…Currently, ultrasound sonography (US), computed tomography (CT), magnetic resonance imaging (MRI), and histopathological examination for tumor biopsy are used for diagnosis. However, distinguishing the three different primary liver tumors is often a challenging task in diagnosis, for which immunohistochemical analysis for specific antigens is a helpful tool: ·-fetoprotein (AFP) and hepatocyto paraffin 1 (HepPar1) for HCC (4)(5)(6)(7)(8) and cytokeratin (CK) 7 and CK19 for ICC (9-11).…”

Section: Introductionmentioning

confidence: 99%

Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer

Nakatsura¹

2009

Int J Oncol

View full text Add to dashboard Cite

Abstract. Primary liver cancers are classified into three types based on their morphology and cytogenetic characteristics hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and combined hepatocellular and cholangiocarcinoma (CHC). It is often difficult to distinguish these liver tumors. Glypican-3 (GPC3) is serological and histochemical marker of hepatocellular carcinoma. In order to separate these three types of liver cancers, we analyzed the GPC3 expression in 85 liver resection specimens, including 46 HCCs, 28 ICCs and 11 CHCs. GPC3 immunohistochemical staining was used to distinguish HCC from ICC by comparing with the conventional biomarker, ·-fetoprotein (AFP). The immunostaining of GPC3 was identified in 78.3% (36/46) of HCCs, 60% (9/15) of well differentiated, 88.9% (16/18) of moderately differentiated and 84.6% (11/13) of poorly differentiated HCCs. It was negative in the ICCs. We confirmed that GPC3 expression is specific to HCC component (8/11, 72.7%) but few samples also showed weakly in ICC component (2/11, 18.2%) of CHC sections among 11 cases compared with HCC biomarkers including AFP and hepatocyto paraffin 1 (HepPar1), and ICC biomarkers cytokeratin (CK) 7 and CK19. Three cases in which the macroscopic features resembled ICC did not express GPC3 even in the pathological HCC component. Most (10/11, 91%) of the pathological cholangiocarcinoma components in CHC showed positive staining for CK7 and CK19. The results of this study suggest that GPC3 is a biomarker that is sensitive and specific to HCC component of CHC, and CK7 and CK19 are markers for pathological cholangiocarcinoma component of CHC.

show abstract

The significance of alpha‐fetoprotein and other tumour markers in differential immunocytochemistry of primary liver tumours

Cited by 88 publications

References 18 publications

Combined Hepatocellular and Cholangiocellular Carcinoma in a Dog.

Combined Hepatocellular and Cholangiocellular Carcinoma in a Dog.

Immunohistochemical Analysis of Hepatocellular and Adenocarcinoma in the Liver: MOC31 Compares Favorably with Other Putative Markers

Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer

Contact Info

Product

Resources

About